Clinical efficacy of Tanreqing combined with cefoperazone sulbactam for treatment of patients with chronic obstructive pulmonary disease and its effect on levels of cytokines
10.3969/j.issn.1008-9691.2018.06.004
- VernacularTitle:痰热清联合头孢哌酮舒巴坦对COPD患者临床疗效及炎症细胞因子水平的影响
- Author:
Xinfeng LEI
1
;
Ningxiang LI
;
Lijie YU
Author Information
1. 哈励逊国际和平医院全科医学科
- Keywords:
Tanreqing;
Chronic obstructive pulmonary disease;
Expel phlegm and relieve asthma;
Clinical therapeutic effect
- From:
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2018;25(6):578-580
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of Tanreqing combined with cefoperazone sulbactam for treatment of patients with chronic obstructive pulmonary disease (COPD) and explore its mechanism. Methods One hundred and twenty eligible COPD patients admitted to the Harrison International Peace Hospital in Hengshui of Hebei Province from June 2015 to August 2017 were selected, their diagnostic criteria were in accordance with the diagnostic guidelines for COPD (in 2007 revision edition) and they were divided into an experimental group and a control group according to the random number table method, with 60 patients in each group. Both groups had the same routine treatment, such as continuous nasal catheter low flow oxygen inhalation, expel phlegm and relieve asthma, and electrolyte disturbance correction. In the control group, cefoperazone sulbactam intravenous drip was given on the basis of conventional treatment; and the experimental group was additionally given Tanreqing intravenous drip on the basis of treatment in the control group. Both groups received 1 course of treatment for 7 days. According to the clinical symptoms, imagelogy, laboratory indexes, the therapeutic effect was evaluated, and the levels of interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) in serum were detected by enzyme linked immunosorbent assay (ELISA). Results After treatment, the levels of IL-2 in serum were significantly higher than those before treatment in both groups (μg/L: control group was 15.5±2.8 vs. 12.7±1.5, experimental group was 18.2±3.2 vs. 11.6±1.3, both P < 0.05), while the levels of TNF-α in serum were decreased compared with those before treatment in both groups (μg/L: control group was 23.8±2.1 vs. 26.9±6.2, experimental group was 20.1±4.3, 27.6±3.7, both P < 0.05). After treatment, the concentration of IL-2 in the serum of the experimental group was significantly higher than that of the control group (μg/L: 18.2±3.2 vs. 15.5±2.8, P < 0.05), and TNF-α level was significantly lower than that of the control group (μg/L: 20.1±4.3 vs. 23.8±2.1, P < 0.05). After 1 course of treatment, the clinical efficacy in the experimental group was significant, and its total effective rate was higher than that in the control group [93.3% (56/60) vs. 86.7% (52/60), P < 0.05], and no adverse reactions were observed during the course of treatment in both groups. Conclusion The therapeutic effect of Tanreqing combined with cefoperazone sulbactam for treatment of patients with COPD is obvious, and it can increase the concentration of IL-2 and reduce the concentration of TNF-α in serum.
